Lung Cancer: Are we up to the Challenge?
Lung Cancer: Are we up to the Challenge?
复制标题
肺癌：我们要面对挑战吗？
DOI：
10.2174/138920210793175903
复制
发表时间：
2010-11
期刊：
影响因子：
2.6
通讯作者：
Giordano A
中科院分区：
文献类型：
--
作者：
Esposito L;Conti D;Ailavajhala R;Khalil N;Giordano A
肺癌是全世界男性和女性癌症死亡的主要原因，每年有超过100万人死亡。非小细胞肺癌（NSCLC）占所有肺癌的约80%。尽管近年来在诊断和治疗策略方面取得了进展，但NSCLC患者的预后很差，基本上是由于缺乏早期诊断工具。然而，在过去的几年中，遗传和生物化学研究提供了更多的信息，蛋白质和基因的突变参与肺肿瘤。此外，最近的蛋白质组学和microRNA的方法已被引入，以帮助生物标志物的发现。在这里，我们想讨论肺癌途径的最新发现，重点是在恶性细胞增殖中起关键作用的遗传和表观遗传因素，以及它们如何有助于诊断和靶向治疗。
Lung cancer is the leading cause of cancer deaths worldwide among both men and women, with more than 1 million deaths annually. Non–small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers. Although recent advances have been made in diagnosis and treatment strategies, the prognosis of NSCLC patients is poor and it is basically due to a lack of early diagnostic tools. However, in the last years genetic and biochemical studies have provided more information about the protein and gene’s mutations involved in lung tumors. Additionally, recent proteomic and microRNA’s approaches have been introduced to help biomarker discovery. Here we would like to discuss the most recent discoveries in lung cancer pathways, focusing on the genetic and epigenetic factors that play a crucial role in malignant cell proliferation, and how they could be helpful in diagnosis and targeted therapy.